Impact of 30 day readmission after left ventricular assist device implantation

Saurabh Gupta, Rebecca J Cogswell, Samit S. Roy, John R. Spratt, Kenneth K. Liao, Cindy M Martin, Ranjit John

Research output: Contribution to journalArticle

Abstract

Early readmission (within 30 days) after left ventricular assist device (LVAD) implantation might be a marker for increased mortality. We retrospectively reviewed the records of 277 adults who underwent continuous-flow LVAD implantation from 2005 through 2015 at our institution. The baseline characteristics of patients who were (versus were not) readmitted within 30 days after LVAD implantation were compared. To assess the impact of 30 day readmission on long-term survival, we used multivariate Cox regression. We also compared the cardiac transplant rate between the two groups. Of the 277 patients, 217 (78.3%) underwent LVAD implantation as a bridge-to-transplant; 76 (27.4%) of the 277 were readmitted within 30 days. The most common reason for readmission was volume overload (23.6%), followed by gastrointestinal bleeding (15.8%). Male gender, previous smoking, a higher baseline creatinine level, higher Model for End Stage Liver Disease Excluding INR (MELD-XI) score, and postoperative gastrointestinal bleeding or stroke were each associated with 30 day readmission. In our final multivariate model, increased mortality was also associated with 30 day readmission (hazard ratio, 1.60; 95% confidence interval, 1.1-2.5). Among the 217 bridge-to-transplant patients, the cardiac transplant rate was similar between the two groups: 18.7 transplants per patient-year among those who were readmitted within 30 days versus 19.7 transplants per patient-year among those who were not (p = 0.26). Among our study patients, 30 day readmission after LVAD implantation was frequent and was associated with increased mortality. It is currently unclear whether the general health of those patients was a factor and whether efforts to reduce 30 day readmission would favorably affect longer-term patient outcomes.

Original languageEnglish (US)
Pages (from-to)252-256
Number of pages5
JournalASAIO Journal
Volume65
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

Left ventricular assist devices
Transplants
Heart-Assist Devices
Mortality
Hemorrhage
Liver
End Stage Liver Disease
International Normalized Ratio
Creatinine
Hazards
Health
Smoking
Stroke
Confidence Intervals
Survival

Keywords

  • 30-day readmission
  • left ventricular assist device
  • mortality
  • transplant rate
  • transplants

PubMed: MeSH publication types

  • Journal Article

Cite this

Impact of 30 day readmission after left ventricular assist device implantation. / Gupta, Saurabh; Cogswell, Rebecca J; Roy, Samit S.; Spratt, John R.; Liao, Kenneth K.; Martin, Cindy M; John, Ranjit.

In: ASAIO Journal, Vol. 65, No. 3, 01.03.2019, p. 252-256.

Research output: Contribution to journalArticle

Gupta, Saurabh ; Cogswell, Rebecca J ; Roy, Samit S. ; Spratt, John R. ; Liao, Kenneth K. ; Martin, Cindy M ; John, Ranjit. / Impact of 30 day readmission after left ventricular assist device implantation. In: ASAIO Journal. 2019 ; Vol. 65, No. 3. pp. 252-256.
@article{418c7bd8b3104df0a325874b590d70a9,
title = "Impact of 30 day readmission after left ventricular assist device implantation",
abstract = "Early readmission (within 30 days) after left ventricular assist device (LVAD) implantation might be a marker for increased mortality. We retrospectively reviewed the records of 277 adults who underwent continuous-flow LVAD implantation from 2005 through 2015 at our institution. The baseline characteristics of patients who were (versus were not) readmitted within 30 days after LVAD implantation were compared. To assess the impact of 30 day readmission on long-term survival, we used multivariate Cox regression. We also compared the cardiac transplant rate between the two groups. Of the 277 patients, 217 (78.3{\%}) underwent LVAD implantation as a bridge-to-transplant; 76 (27.4{\%}) of the 277 were readmitted within 30 days. The most common reason for readmission was volume overload (23.6{\%}), followed by gastrointestinal bleeding (15.8{\%}). Male gender, previous smoking, a higher baseline creatinine level, higher Model for End Stage Liver Disease Excluding INR (MELD-XI) score, and postoperative gastrointestinal bleeding or stroke were each associated with 30 day readmission. In our final multivariate model, increased mortality was also associated with 30 day readmission (hazard ratio, 1.60; 95{\%} confidence interval, 1.1-2.5). Among the 217 bridge-to-transplant patients, the cardiac transplant rate was similar between the two groups: 18.7 transplants per patient-year among those who were readmitted within 30 days versus 19.7 transplants per patient-year among those who were not (p = 0.26). Among our study patients, 30 day readmission after LVAD implantation was frequent and was associated with increased mortality. It is currently unclear whether the general health of those patients was a factor and whether efforts to reduce 30 day readmission would favorably affect longer-term patient outcomes.",
keywords = "30-day readmission, left ventricular assist device, mortality, transplant rate, transplants",
author = "Saurabh Gupta and Cogswell, {Rebecca J} and Roy, {Samit S.} and Spratt, {John R.} and Liao, {Kenneth K.} and Martin, {Cindy M} and Ranjit John",
year = "2019",
month = "3",
day = "1",
doi = "10.1097/MAT.0000000000000812",
language = "English (US)",
volume = "65",
pages = "252--256",
journal = "ASAIO Journal",
issn = "1058-2916",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Impact of 30 day readmission after left ventricular assist device implantation

AU - Gupta, Saurabh

AU - Cogswell, Rebecca J

AU - Roy, Samit S.

AU - Spratt, John R.

AU - Liao, Kenneth K.

AU - Martin, Cindy M

AU - John, Ranjit

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Early readmission (within 30 days) after left ventricular assist device (LVAD) implantation might be a marker for increased mortality. We retrospectively reviewed the records of 277 adults who underwent continuous-flow LVAD implantation from 2005 through 2015 at our institution. The baseline characteristics of patients who were (versus were not) readmitted within 30 days after LVAD implantation were compared. To assess the impact of 30 day readmission on long-term survival, we used multivariate Cox regression. We also compared the cardiac transplant rate between the two groups. Of the 277 patients, 217 (78.3%) underwent LVAD implantation as a bridge-to-transplant; 76 (27.4%) of the 277 were readmitted within 30 days. The most common reason for readmission was volume overload (23.6%), followed by gastrointestinal bleeding (15.8%). Male gender, previous smoking, a higher baseline creatinine level, higher Model for End Stage Liver Disease Excluding INR (MELD-XI) score, and postoperative gastrointestinal bleeding or stroke were each associated with 30 day readmission. In our final multivariate model, increased mortality was also associated with 30 day readmission (hazard ratio, 1.60; 95% confidence interval, 1.1-2.5). Among the 217 bridge-to-transplant patients, the cardiac transplant rate was similar between the two groups: 18.7 transplants per patient-year among those who were readmitted within 30 days versus 19.7 transplants per patient-year among those who were not (p = 0.26). Among our study patients, 30 day readmission after LVAD implantation was frequent and was associated with increased mortality. It is currently unclear whether the general health of those patients was a factor and whether efforts to reduce 30 day readmission would favorably affect longer-term patient outcomes.

AB - Early readmission (within 30 days) after left ventricular assist device (LVAD) implantation might be a marker for increased mortality. We retrospectively reviewed the records of 277 adults who underwent continuous-flow LVAD implantation from 2005 through 2015 at our institution. The baseline characteristics of patients who were (versus were not) readmitted within 30 days after LVAD implantation were compared. To assess the impact of 30 day readmission on long-term survival, we used multivariate Cox regression. We also compared the cardiac transplant rate between the two groups. Of the 277 patients, 217 (78.3%) underwent LVAD implantation as a bridge-to-transplant; 76 (27.4%) of the 277 were readmitted within 30 days. The most common reason for readmission was volume overload (23.6%), followed by gastrointestinal bleeding (15.8%). Male gender, previous smoking, a higher baseline creatinine level, higher Model for End Stage Liver Disease Excluding INR (MELD-XI) score, and postoperative gastrointestinal bleeding or stroke were each associated with 30 day readmission. In our final multivariate model, increased mortality was also associated with 30 day readmission (hazard ratio, 1.60; 95% confidence interval, 1.1-2.5). Among the 217 bridge-to-transplant patients, the cardiac transplant rate was similar between the two groups: 18.7 transplants per patient-year among those who were readmitted within 30 days versus 19.7 transplants per patient-year among those who were not (p = 0.26). Among our study patients, 30 day readmission after LVAD implantation was frequent and was associated with increased mortality. It is currently unclear whether the general health of those patients was a factor and whether efforts to reduce 30 day readmission would favorably affect longer-term patient outcomes.

KW - 30-day readmission

KW - left ventricular assist device

KW - mortality

KW - transplant rate

KW - transplants

UR - http://www.scopus.com/inward/record.url?scp=85064870714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064870714&partnerID=8YFLogxK

U2 - 10.1097/MAT.0000000000000812

DO - 10.1097/MAT.0000000000000812

M3 - Article

C2 - 29750684

AN - SCOPUS:85064870714

VL - 65

SP - 252

EP - 256

JO - ASAIO Journal

JF - ASAIO Journal

SN - 1058-2916

IS - 3

ER -